TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05776212

Intervention type: RADIATION
Intervention: 18F-fluoride PET
Description: Positron emission tomography using 18F-fluoride as a tracer

Intervention type: RADIATION
Intervention: 18F-fluoride PET
Description: Positron emission tomography using 18F-fluoride as a tracer

Intervention type: RADIATION
Intervention: 18F-fluoride PET
Description: Positron emission tomography using 18F-fluoride as a tracer

Intervention type: RADIATION
Intervention: 18F-fluoride PET
Description: Positron emission tomography using 18F-fluoride as a tracer
Study: NCT05253677

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CT-guided PCI
Description: CT-guided PCI with standardized pre-procedural planning and online guidance.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IVUS-guided PCI
Description: use of IVUS during PCI procedure (standard of care)
Study: NCT05469750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalpiciclib+ letrozole +capecitabine
Description: Continue medication to disease progression
Study: NCT05629403

Intervention type: OTHER
Intervention: observe
Description: no intervention

Intervention type: OTHER
Intervention: observe
Description: no intervention
Study: NCT05494177

Intervention type: DIAGNOSTIC_TEST
Intervention: bUDVA, bUIRA, bUNRA, bUICPS, bUNCPS
Description: All participants will be assessed on the following clinical indexes:~1. Binocular uncorrected distant visual acuity (bUDVA) at four meters distance~2. Binocular uncorrected intermediate reading acuity (bUIRA) at 60 cm~3. Binocular uncorrected near reading acuity (bUNVA) at 40 cm~4. Binocular uncorrected intermediate Critical Print Size (bUICPS) at 60 cm~5. Binocular uncorrected near Critical Print Size (bUNCPS) at 40 cm~All the above parameters are obtained using the Democritus Digital Acuity \& Reading Test (DDART).

Intervention type: DIAGNOSTIC_TEST
Intervention: bUDVA, bUIRA, bUNRA, bUICPS, bUNCPS
Description: All participants will be assessed on the following clinical indexes:~1. Binocular uncorrected distant visual acuity (bUDVA) at four meters distance~2. Binocular uncorrected intermediate reading acuity (bUIRA) at 60 cm~3. Binocular uncorrected near reading acuity (bUNVA) at 40 cm~4. Binocular uncorrected intermediate Critical Print Size (bUICPS) at 60 cm~5. Binocular uncorrected near Critical Print Size (bUNCPS) at 40 cm~All the above parameters are obtained using the Democritus Digital Acuity \& Reading Test (DDART).

Intervention type: DIAGNOSTIC_TEST
Intervention: Contrast sensitivity
Description: Contrast sensitivity is assessed with the Pelli-Robson test.

Intervention type: DIAGNOSTIC_TEST
Intervention: Contrast sensitivity
Description: Contrast sensitivity is assessed with the Pelli-Robson test.
Study: NCT06191653

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness and Self-Compassion for Caregivers working in Youth Detention Centres
Description: The adapted form of the MSC is a 12-session structured program, delivered on a weekly basis in group. It intends to cultivate a compassionate-self as well as increase the awareness of personal patterns of functioning and learning to respond to them in a kind and courageous way. Each session lasts about 2 hours. Each session has the following structure: Grounding exercise; sharing individual insights about the weekly practice; Reviewing the previous session and link for the session theme; coffee break; soft landing exercise; Formal/Informal practice(s); Session summary and challenges to be applied during the week; Session evaluation and take-off. Each participant receives a manual with the contents shared in each session as well as some space for individual reflections. On the day after each session, a summary email is sent to the participants, resuming the contents and with records of the (in)formal practices delivered. All the sessions will be delivered in a space on each YDC.
Study: NCT04301960

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single task training
Description: The single task group includes balance gaining and cognitive training. The single task group will have 30-40 minutes of single-task training for 3 sessions per week for 8 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual task training
Description: The dual-task group includes CSRT Mat training. The dual-task group will have CSRT Mat training for 30-40 minutes of dual-task training for 3 sessions per week for 8 weeks.
Study: NCT06044974

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nd-YAG Fotona
Description: four combined therapy sessions using 1064 nm Nd-YAG laser (once/week)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidermal Growth Factor
Description: Epidermal growth factor EGF-genesis by Dermaquel Paris n into masseter and temporalis muscles. Each muscle will be divided into 3 zones; origin, body and insertion for masseter muscle, anterior, middle, and posterior for temporalis muscle
Study: NCT05536011

Intervention type: DRUG
Intervention: Pitolisant
Description: Exposure to at least one dose of pitolisant at any time during pregnancy

Intervention type: DRUG
Intervention: Pitolisant
Description: Exposure to at least one dose of pitolisant at any time during pregnancy

Intervention type: DRUG
Intervention: Comparator Products
Description: Exposure to at least one dose of a comparator product at any time during pregnancy

Intervention type: DRUG
Intervention: Comparator Products
Description: Exposure to at least one dose of a comparator product at any time during pregnancy
Study: NCT06067568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutikizumab Dose A
Description: Injection; subcutaneous (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutikizumab Dose A
Description: Injection; subcutaneous (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutikizumab Dose B
Description: Injection; subcutaneous (SC)
Study: NCT05960617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Oral administration of Empagliflozin:~The starting dose was 0.3 mg/kg/day in 2 divided doses for 3 months. If the subject had an absolute neutrophil count \> 1.0 × 10\^9/L and clinical improvement (decreased number of infections and/or decreased IBD activity within 3 months), the maintenance dose was maintained.~If the subject had an absolute neutrophil count \< 1.0 × 10\^9/L but clinical improvement (decreased number of infections and/or decreased IBD activity within 3 months), the maintenance dose was maintained and reassessed 1 month later.~If the subject had an absolute neutrophil count \< 1.0 × 10\^9/L and no clinical improvement (no change in number of infections and/or no change in IBD activity within 3 months), the dose was increased by 0.1 mg/kg/day and reassessed 3 months later.~Assessments were then performed every 3 months with the same dose modification criteria as above.
Study: NCT05221671

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: information leaflet
Description: Leaflets prepared to inform about anesthesia and endoscopic procedure will be given to both parents and pediatric patients. A standard leaflet has been prepared for parents. Two leaflets have been prepared for children under the age of 12 and for adolescent patients over the age of 12. Unlike routine hospital information forms, all leaflets designed and prepared as a cartoon book. It is narrated using photographs of the materials and toys in the endoscopy room. It was predicted that there would be a difference between the groups who read and did not read this information leaflet in terms of anxiety levels and anesthesia knowledge levels.
Study: NCT05822219

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: COVID-19 vaccine and booster training, and importance
Description: COVID-19 vaccine and booster information training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COVID-19 vaccine and booster training, and importance
Description: COVID-19 vaccine and booster information training
Study: NCT06391060

Intervention type: PROCEDURE
Intervention: Impact of Gender on Davinci rectal surgery
Description: gender-specific considerations in the surgical management and post-operative care of rectal cancer patients undergoing robotic surgery
Study: NCT04849247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTA-FAPI, 177Lu-DOTA-FAPI
Description: PET imaging using 68Ga-DOTA-FAPI will be used to diagnose patients who are eligible for treatment with the 177Lu-DOTA-FAPI.
Study: NCT05521945

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermittent Fasting
Description: 16 hours fasting and 8 hours eating window

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Calorie Restricted Diet
Description: The customized diet plan will be given to the participants according to their calorie intake requirements

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Normal dietary intake
Description: normal diet without any customization
Study: NCT05508620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus for Injection (Albumin-bound)
Description: Intravenous infusion
Study: NCT05715866

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-invasive neuromodulation through the Nesa device
Description: patients receive non-invasive neurostimulation through the Nesa device

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic exercise
Description: patients receive adapted therapeutic exercise

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: sleep hygiene measures
Description: caregivers receive a brochure with sleep hygiene measures
Study: NCT00828880

Intervention type: DEVICE
Intervention: DRX9000
Description: DRX9000 - non-invasive spinal decompression. Treatments 28 min 5 x/wk x 2wks, 3x/wk x 2 wks, 2x/wk x 2 wks for a total of 20 treatments in a 6-week period
Study: NCT04841356

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate Compression Garment
Description: Immediately following surgery, in the operating room, the compression garment will be donned on the surgical limb. The garment is set to the following pressures to facilitate gradient compression: 40mm Hg (lower leg), 30mm Hg (knee), 20 mm Hg (thigh) utilizing a standardized garment tensioning tool. Subjects will wear the garment during all waking hours (target wear time of 12 hours daily) for the first 3 weeks after surgery. Additionally, subjects will be instructed to perform a therapeutic exercise program designed to manage swelling by targeting major lower extremity musculature (gastrocnemius, soleus, quadriceps, hamstrings, and gluteal musculature) and promoting venous and lymphatic return. These exercises will be performed five times daily during the first three weeks after surgery.~Subjects will receive standard of care rehabilitation following surgery as directed and coordinated by the surgeon and participant. This rehabilitation is not part of this research study.
Study: NCT05535933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-523(300mg PO QD)
Description: No more than two doses will be explored

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05239637

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heparin stopped before ECMO decannulation
Description: Heparin has been stopped for 1 hour before ECMO decannulation;The cannulas can be removed immediately with clots larger than 5 mm or enlarging clots in the circuit.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heparin reduced after ECMO decannulation
Description: Heparin gradually reduced within 24 hours after ECMO decannulation, If excess bleeding occured,decrease the heparin infusion rapidly or turn the heparin off immediately. Protamine can be given to reversing heparin if necessary.
Study: NCT05833763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: Glofitamab is provided as liquid concentrate for IV infusion. Each vial contains 10mg of glofitamab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Pirtobrutinib is supplied as immediate release film-coated tablets containing 50 mg, or 100 mg of active compound. Tablets are supplied in labelled, HDPE bottles and sealed with child-resistant closures.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab is provided as a single dose 1000 mg liquid concentrate for infusion containing of 25 mg/mL obinutuzumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab is provided as a liquid concentrate for IV infusion. Each vial contains 200mg/10mL concentrate solution
Study: NCT05740072

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drying before wrapping
Description: Immediately after birth, the infant's body will be dried before wrapping in a plastic bag

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No drying before wrapping
Description: Immediately after birth, the infant will be put in a plastic bag without wrapping
Study: NCT05956015

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stable isotopes
Description: The tracer 2H5-phenylalanine is an essential amino acid labeled with deuterium that is a stable isotope, i.e. no radiation is emitted, but the tracer can still be assessed by a combination of gas chromatography and mass spectrometry. The tracer has no measurable effects, but are used for assessment of human physiology.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stable isotopes
Description: The tracer 2H5-phenylalanine is an essential amino acid labeled with deuterium that is a stable isotope, i.e. no radiation is emitted, but the tracer can still be assessed by a combination of gas chromatography and mass spectrometry. The tracer has no measurable effects, but are used for assessment of human physiology.
Study: NCT04594980

Intervention type: PROCEDURE
Group type: OTHER
Intervention: lumbar fusion
Description: Transforaminal Lumbar Interbody Fusion will be performed using minimally invasive approach or traditional open technique.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: lumbar fusion
Description: Transforaminal Lumbar Interbody Fusion will be performed using minimally invasive approach or traditional open technique.
Study: NCT06200662

Intervention type: OTHER
Group type: OTHER
Intervention: Analgesic strategies during the S visit:
Description: Analgesic strategies during the S visit: standard and recommended non-pharmacological analgesic strategies used by the CRI: administration of sugar solution, support for non-nutritive sucking with a dummy and wrapping in a nappy.

Intervention type: OTHER
Group type: OTHER
Intervention: Analgesic strategies during the S visit:
Description: Analgesic strategies during the S visit: standard and recommended non-pharmacological analgesic strategies used by the CRI: administration of sugar solution, support for non-nutritive sucking with a dummy and wrapping in a nappy.

Intervention type: OTHER
Group type: OTHER
Intervention: Analgesic strategies at visit M
Description: Analgesic strategies at visit M: overall non-pharmacological analgesic strategies carried out by the mother: sucking on a sugar solution, supporting non-nutritive sucking with a dummy, contact, etc.

Intervention type: OTHER
Group type: OTHER
Intervention: Analgesic strategies at visit M
Description: Analgesic strategies at visit M: overall non-pharmacological analgesic strategies carried out by the mother: sucking on a sugar solution, supporting non-nutritive sucking with a dummy, contact, etc.
Study: NCT05878301

Intervention type: OTHER
Group type: OTHER
Intervention: vegetable and protein first followed by carbohydrates (VPF) meal sequence
Description: vegetable and protein first followed10 min later by carbohydrates (VPF) meal sequence
Study: NCT04433273

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Electrical vestibular nerve stimulation
Description: Electrical vestibular nerve stimulation using a headset device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electrical vestibular nerve stimulation
Description: Electrical vestibular nerve stimulation using a headset device
Study: NCT06006689

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Qishen Yiqi Dripping Pills placebo 3 bags
Description: Qishen Yiqi Dripping Pills placebo contain Qishen Yiqi dripping pills placebo 3 bags(0.52g dripping pills placebo per bag),take orally after meals, 3 times a day for 12weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose Qishen Yiqi Dripping Pills 3 bags
Description: Low dose Qishen Yiqi Dripping Pills contain Qishen Yiqi dripping pills 2 bags(0.52g dripping pills per bag) and Qishen Yiqi dripping pills placebo 1 bag(0.52g dripping pills placebo per bag),take orally after meals, 3 times a day for 12weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose Qishen Yiqi Dripping Pills 3 bags
Description: High dose Qishen Yiqi Dripping Pills contain Qishen Yiqi dripping pills 3 bags(0.52g dripping pills per bag),take orally after meals, 3 times a day for 12weeks
Study: NCT04918667

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Berberine incorporated in gamma cyclodextrin
Description: Experimental modified product. One capsule contains 250 mg of Berberine from Indian Barberry (Berberis aristate DC.) Bark and Root Extract incorporated in gamma-cyclodextrin

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Berberine
Description: Active comparator. One capsule contains 500 mg of Berberine from Indian Barberry (Berberis aristate DC.) Bark and Root Extract
Study: NCT06036303

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasr fascial closure device
Description: Nasr fascial closure device is a novel device for fascial closure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Berci Fascial Closure Device
Description: Berci Fascial Closure Device is a known device for fascial closure
Study: NCT04803331

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SPIO-enhanced MRI
Description: SPIO is peritumorally injected. A T2\*-weighted iron sensitive MRI scan is performed 1 hour later to localize and assess the sentinel lymph nodes.
Study: NCT06183957

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hydrotherapy group
Description: When women in this group are taken to their labor rooms (when the dilation is 4-5cm), they should be standing or standing, depending on their preferences, on their waist, abdomen or whole body, with the temperature of the water between 32-37 °C (the temperature preferred by the woman will be applied) for at least 20 minutes. Sitting shower application will be performed under the observation of the researcher midwife. The temperature of the flowing water will be measured with a bucket and a thermometer that helps evaluate the temperature. The application will be repeated when the dilation is 6-8 cm.
Study: NCT06284889

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural activation
Description: Session 1: Face-to-face; Psychoeducation about depression; treatment rationale for Behavioral Activation (BA); rationale and instructions for activity log;~Session 2: Via telephone; Discussion of life goals and values; planning of activities aligned with life goals and values for coming week~Session 3: Via telephone; Troubleshooting any problems carrying out activities; planning activities aligned with life goals and values for coming week.~Session 4: Via telephone; Troubleshooting any problems carrying out activities; planning activities aligned with life goals and values for the coming week; instructing the participant to independently continue to plan activities for the coming month.~Session 5: Via telephone; Troubleshooting any problems carrying out activities; reviewing treatment; stressing the importance of continuing to engage in activities aligned with life goals and values; creating a maintenance plan.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual (TAU)
Description: Treatment as usual regarding depression received at their primary care centre.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: Treatment as usual regarding depression received at their primary care centre.
Study: NCT06331936

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion regulation
Description: Each participant will attend four intervention sessions. They will also be invited to a booster Session, where they will be invited for interviews to share what they have gained from the sessions. The contents of the intervention and the booster session are as follows: (1) understand emotions, (2) attention and positivity, (3) emotional regulation, (4) connectedness and intimacy, and (5) review and sharing.
Study: NCT05902689

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: alveolar ridge preservation with bio-oss collagen
Description: Alveolar ridge preservation with bio-oss collagen is a surgical method that reduces or limits the physiological resorption of alveolar bone after tooth extraction by implanting bio-oss collagen in the socket and covering the biological barrier membrane.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: alveolar ridge preservation with sticky bone
Description: Alveolar ridge preservation with sticky bone is a surgical method that reduces or limits the physiological resorption of alveolar bone after tooth extraction by implanting sticky bone in the socket and covering the biological barrier membrane.
Study: NCT04226742

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ADAPT Platform (Treatment)
Description: The ADAPT platform consists of 2 modules based on evidence-based strategies from cognitive-behavioral therapy including cognitive restructuring and behavioral experiments. The platform includes didactic material, interactive tools, and crowd-features. Crowd-features are present to increase personal relevance of content and to promote engagement with the ADAPT platform through accountability. Crowd-features include requesting, responding, and exemplars.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ADAPT Comparison (Control)
Description: The control platform is a self-guided version of the ADAPT platform that includes no crowd-features. As such it will include only didactic material on cognitive restructuring and behavioral experiments and interactive tools.
Study: NCT05236582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herombopag
Description: The subjects will initiate treatment with 7.5 mg/d Herombopag. Platelet counts is obtained weekly and dose adjustment should be done according to platelet counts, and maximum dose should not exceed 7.5 mg daily. Subjects whose platelet count ≤100×109/L，the Herombopag dose will maintain. If platelet count \>100×109/L for 2 weeks, the subjects need to reduce the dose of Herombopag to the next lower dose or lower frequency. If subjects whose platelet count exceeds 100×109/L for 4 weeks，already have reduced the dose of Herombopag to 2.5mg once every other day or lower frequency during the treatment period, Herombopag can be stopped for observation, until platelet counts fall below 100×109/L. If the subjects do not need further chemotherapy or radiotherapy, the subjects can taper off Herombopag if the platelet is greater than 50×109/L.